Drugs / DC/AML Fusion Vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07374029 | Feb 2026 → Oct 2027 expected | acute myeloid leukemia | David Avigan | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DC/AML Fusion Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07374029 ↗ |
| Modality | Vaccine | “DC/AML fusion vaccine (immune cell vaccine)” NCT07374029 ↗ |
| Route | Subcutaneous | “via subcutaneous injection (under the skin)” NCT07374029 ↗ |